Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials
- 23 November 2010
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 28 (50), 7993-8000
- https://doi.org/10.1016/j.vaccine.2010.09.035
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trialThe Lancet, 2007
- Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case–control study in Nepalese children 5 years after immunizationVaccine, 2007
- A live, attenuated recombinant West Nile virus vaccineProceedings of the National Academy of Sciences, 2006
- Cutaneous Delivery of a Live, Attenuated Chimeric Flavivirus Vaccines against Japanese Encephalitis (ChimeriVaxTM-JE) in Non-Human PrimatesHuman Vaccines, 2005
- Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax™-JE experimental vaccineVaccine, 2004
- New initiatives for the control of Japanese encephalitis by vaccination:Vaccine, 2000
- Immunogenicity, Genetic Stability, and Protective Efficacy of a Recombinant, Chimeric Yellow Fever-Japanese Encephalitis Virus (ChimeriVax-JE) as a Live, Attenuated Vaccine Candidate against Japanese EncephalitisVirology, 1999
- Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primatesVaccine, 1999
- Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control studyThe Lancet, 1996
- Protection against Japanese Encephalitis by Inactivated VaccinesNew England Journal of Medicine, 1988